MedTrace Logo

Investigation of Effectiveness of Local Antibiotic With Platelet Rich Fibrin on Third Molar Surgery Outcomes In Vivo

NCT05678296 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2023-01-11

No results posted yet for this study

Summary

The aim of this study was investigate the effectiveness of Local Antibiotic Applications With Platelet Rich Fibrin on Third Molar Surgery Outcomes In Vivo and In Vitro. The study included a total of 60 patients with impacted mandibular third molar. Patients were evaluated in 3 randomly separated groups. For the first and second group, Platelets Rich Fibrin+ local antibiotics were applied into the tooth socket. For the first group, amoxicillin was applied and for the second group, clindamycin was applied. There was a control group which only Platelets Rich Fibrin was applied into the socket. The outcome variables were pain, swelling, the number of analgesics taken, and trismus. These variables were also assessed based on first, second, third, and seventh days following the operation.

Conditions

  • Impacted Wisdom Tooth
  • Pain
  • Staphylococcus Aureus

Interventions

DIAGNOSTIC_TEST

Diagnosis

All of the patients withstand a radiological examination, including panoramic radiography, and all were handled by the same surgeon and assistant.

DRUG

Analgesic

Analgesics are prescribed for the patients for all groups.

PROCEDURE

traditional osteotomies

In all groups the flap incision was triangular in shape which avoids muscle involvement (Archer flap).

BIOLOGICAL

Platelet Rich Fibrin

Platelet rich fibrin (PRF), is an example and popular procedure for accelerate healing of soft and hard tissue because of the presence of various growth factors.a blood sample was taken without anticoagulant in 10 mL glass-coated plastic tubes that were immediately centrifuged (Elektro-mag M415P) at 3,000 rpm for 10 min (approximately 400 g) (13). The platelet-poor plasma that accumulated at the top of the tubes was discarded.PRF was dissected approximately 2 mm below its contact point with the red corpuscles situated beneath, to include any remaining platelets that may have localized below the junction between the PRF and red corpuscles.

DRUG

Antibiotic

no systemic antibiotics are prescribed for the patients for all groups.

Sponsors & Collaborators

  • Ceren Melahat Donmezer

    lead OTHER

Principal Investigators

  • Ceren Melahat Dönmezer · Near East University

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-20
Primary Completion
2022-02-17
Completion
2022-04-23

Countries

  • Cyprus

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05678296 on ClinicalTrials.gov